This video brief features Dr. Jung-Sun Kim reporting from AHA 2025 in New Orleans. He highlights the rationale and design of the ADAPT AF-DES trial, which investigates optimal antithrombotic therapy beyond 12 months in patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The discussion contextualizes these findings within current guideline recommendations and highlights considerations for individualized therapy.
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents

Transcript
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
videoPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more
videoOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Show more
videoDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more
videoPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more
videoDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more
videoThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more
videoThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more
videoHighlights of the Latest Hypertension Guidelines
Show more
videoClinical Perspective on New Therapies in Resistant Hypertension
Show more
Overview
This video brief features Dr. Jung-Sun Kim reporting from AHA 2025 in New Orleans. He highlights the rationale and design of the ADAPT AF-DES trial, which investigates optimal antithrombotic therapy beyond 12 months in patients with atrial fibrillation (AF) who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents (DES). The discussion contextualizes these findings within current guideline recommendations and highlights considerations for individualized therapy.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
videoPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Show more
videoOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Show more
videoDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Show more
videoPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Show more
videoDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Show more
videoThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more
videoThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
Show more
videoHighlights of the Latest Hypertension Guidelines
Show more
videoClinical Perspective on New Therapies in Resistant Hypertension
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?








